GO:0004607 phosphatidylcholine-sterol O-acyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004607 describes the enzymatic activity that transfers a fatty acyl chain from phosphatidylcholine (lecithin) to a sterol, producing a sterol ester and 1-acylglycerophosphocholine.
• In humans, this activity is primarily carried out by lecithin-cholesterol acyltransferase (LCAT), a secreted enzyme that esterifies free cholesterol on high-density lipoprotein (HDL) particles.
• LCAT activity is essential for reverse cholesterol transport and HDL maturation, and its deficiency causes familial LCAT deficiency, a rare disorder with corneal opacities, anemia, and renal disease.
• LCAT is activated by apolipoproteins, particularly apoA-I, and also by apoE isoforms, which modulate its catalytic efficiency.
• Both loss-of-function and gain-of-function studies have linked LCAT to atherosclerosis, making it a target for HDL-based therapies.
• CRISPR-based knockout, knock-in, and overexpression models enable precise dissection of LCAT function in lipid metabolism and disease.
Description
Phosphatidylcholine-sterol O-acyltransferase activity (GO:0004607) is a molecular function that catalyzes the transfer of an acyl group from phosphatidylcholine to a sterol, yielding a sterol ester and 1-acylglycerophosphocholine. This reaction is central to cholesterol homeostasis and lipoprotein metabolism, as it converts free cholesterol into cholesteryl esters, which are more hydrophobic and can be packaged into lipoprotein cores. In humans, the principal enzyme exhibiting this activity is lecithin-cholesterol acyltransferase (LCAT), a secreted enzyme synthesized mainly in the liver and found in plasma associated with high-density lipoproteins (HDL). Because of its role in reverse cholesterol transport, LCAT has been extensively studied as a determinant of HDL levels and cardiovascular risk. Researchers study GO:0004607 to understand how cells and organisms manage cholesterol transport, how HDL particles mature, and how defects in this activity lead to disease. Familial LCAT deficiency, caused by mutations in the LCAT gene, results in corneal opacities, anemia, and progressive renal failure, highlighting the physiological importance of this activity. Moreover, therapeutic strategies aimed at increasing LCAT activity or mimicking its effects are being explored for atherosclerosis and other lipid disorders. The availability of CRISPR-based models now allows precise manipulation of LCAT and related genes to test causality and dissect mechanisms.
phosphatidylcholine-sterol O-acyltransferase activity At A Glance
| GO ID | GO:0004607 |
|---|---|
| GO term | phosphatidylcholine-sterol O-acyltransferase activity |
| Ontology | molecular_function |
| Synonym | LCAT activity; lecithin-cholesterol acyltransferase activity; phosphatidylcholine:sterol O-acyltransferase activity |
| Major function | Transfer of an acyl chain from phosphatidylcholine to a sterol, producing a sterol ester and 1-acylglycerophosphocholine |
| Reaction | phosphatidylcholine + a sterol = a sterol ester + 1-acylglycerophosphocholine |
| Main enzyme in humans | LCAT (lecithin-cholesterol acyltransferase) |
| Cofactors/activators | Apolipoproteins, particularly apoA-I and apoE isoforms |
| Subcellular location | Secreted; associated with HDL in plasma |
What Is GO:0004607?
GO:0004607, phosphatidylcholine-sterol O-acyltransferase activity, is defined as the catalysis of the reaction: phosphatidylcholine + a sterol = a sterol ester + 1-acylglycerophosphocholine. In other words, it is an enzymatic activity that removes a fatty acid from phosphatidylcholine (lecithin) and attaches it to a sterol molecule, typically cholesterol, forming a sterol ester and a lysophosphatidylcholine (1-acylglycerophosphocholine). This activity is synonymous with LCAT activity, lecithin-cholesterol acyltransferase activity, and phosphatidylcholine:sterol O-acyltransferase activity.
Why Is phosphatidylcholine-sterol O-acyltransferase activity Important in Cell Biology?
GO:0004607 is critical because it represents the principal route for esterification of free cholesterol in plasma, a step required for the maturation of HDL and for reverse cholesterol transport, the process by which excess cholesterol is moved from peripheral tissues to the liver for excretion. Dysregulation of this activity is linked to dyslipidemias, atherosclerosis, and rare genetic disorders such as familial LCAT deficiency. Understanding its mechanism and regulation informs the development of therapies targeting HDL and cholesterol metabolism.
• Essential for HDL maturation and reverse cholesterol transport.
• Deficiency causes familial LCAT deficiency, with corneal opacities, anemia, and renal failure.
• Modulates atherosclerosis susceptibility in animal models and humans.
• Target for HDL-raising therapies and cardiovascular drug development.
• Regulated by apolipoproteins, especially apoA-I and apoE isoforms.
• Provides a model for studying enzyme-substrate interactions at lipid-water interfaces.
• Relevant to cholesterol gallstone formation and lipid absorption.
• Used as a biomarker of HDL function in clinical studies.
• Enables CRISPR-based dissection of lipid metabolism pathways.
What Happens During phosphatidylcholine-sterol O-acyltransferase activity?
Substrate binding and interfacial activation
In simple terms: The enzyme grabs onto a lipid particle and positions itself to access its substrates.
LCAT is a soluble enzyme that acts at the surface of lipoproteins, particularly HDL. It binds to the phospholipid monolayer, where it interacts with phosphatidylcholine and free cholesterol. The binding is facilitated by apolipoproteins, especially apoA-I, which activates the enzyme and presents substrates in a favorable orientation. This interfacial activation is a key regulatory step, as LCAT activity is low in the absence of activators.
Acyl transfer and product formation
In simple terms: The enzyme snips a fatty acid from lecithin and attaches it to cholesterol.
Once bound, LCAT catalyzes the transfer of the sn-2 acyl chain from phosphatidylcholine to the hydroxyl group of cholesterol, forming a cholesteryl ester and lysophosphatidylcholine (1-acylglycerophosphocholine). This reaction is reversible in principle but proceeds toward esterification under physiological conditions because the products are rapidly removed or partitioned into the lipoprotein core.
Product partitioning and HDL remodeling
In simple terms: The cholesteryl ester sinks into the HDL core, changing the particle.
The newly formed cholesteryl ester is highly hydrophobic and partitions into the core of the HDL particle, converting a surface cholesterol molecule into a core lipid. This drives the maturation of HDL from discoidal to spherical particles and maintains a gradient that promotes efflux of free cholesterol from cells. Lysophosphatidylcholine can be further metabolized or removed by other enzymes.
Role in reverse cholesterol transport
In simple terms: This activity helps carry cholesterol from tissues back to the liver.
By esterifying cholesterol on HDL, LCAT activity maintains the concentration gradient that favors cholesterol efflux from peripheral cells, including macrophages. The cholesteryl esters are ultimately delivered to the liver via scavenger receptor BI (SR-BI) or transferred to apoB-containing lipoproteins by cholesteryl ester transfer protein (CETP). This pathway is central to reverse cholesterol transport and atheroprotection.
Key Genes Involved in GO:0004607 phosphatidylcholine-sterol O-acyltransferase activity
The following genes and proteins are directly or indirectly involved in phosphatidylcholine-sterol O-acyltransferase activity, its regulation, and its physiological context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LCAT | Catalyzes the acyl transfer from phosphatidylcholine to cholesterol | Primary enzyme for GO:0004607; mutations cause familial LCAT deficiency |
| APOA1 | Major apolipoprotein activator of LCAT; structural component of HDL | Activates LCAT and determines HDL levels |
| APOE | Apolipoprotein that can activate LCAT in an isoform-specific manner | Modulates LCAT activity and lipid metabolism |
| APOA2 | Apolipoprotein that can inhibit or modulate LCAT activity | Regulates LCAT in HDL subpopulations |
| APOB | Structural protein of LDL and VLDL; can accept cholesteryl esters | Indirectly affects LCAT-mediated cholesterol transport |
| CETP | Transfers cholesteryl esters from HDL to apoB lipoproteins | Interacts with LCAT pathway in reverse cholesterol transport |
| SCARB1 | SR-BI receptor mediates selective uptake of HDL cholesteryl esters | Downstream of LCAT in reverse cholesterol transport |
| ABCA1 | Cholesterol efflux pump to lipid-poor apoA-I | Provides substrate for LCAT on nascent HDL |
| ABCG1 | Cholesterol efflux pump to mature HDL | Contributes to cholesterol pool for LCAT |
| NR1H2 | LXR beta; regulates cholesterol metabolism genes | Transcriptional regulation of LCAT and related genes |
| NR1H3 | LXR alpha; regulates cholesterol efflux and HDL genes | Modulates LCAT expression and activity |
| SREBF2 | Sterol regulatory element-binding protein 2 | Controls cholesterol synthesis and uptake, affecting substrate availability |
| PPARG | Peroxisome proliferator-activated receptor gamma | Regulates lipid metabolism and HDL levels |
| CYP7A1 | Cholesterol 7-alpha-hydroxylase; rate-limiting for bile acid synthesis | Determines cholesterol elimination downstream of LCAT |
| LIPC | Hepatic lipase; remodels HDL and influences LCAT activity | Modifies HDL phospholipid content |
| PLTP | Phospholipid transfer protein; modulates HDL size and LCAT activity | Interacts with LCAT in HDL remodeling |
| PON1 | Paraoxonase 1; associated with HDL, may protect LCAT | Modulates oxidative stress and HDL function |
| GPIHBP1 | Endothelial lipase chaperone; not directly LCAT but lipid processing | Context for lipoprotein metabolism |
How Is phosphatidylcholine-sterol O-acyltransferase activity Regulated?
LCAT activity is regulated at multiple levels. Transcriptional regulation of the LCAT gene involves liver X receptors (LXRs) and other nuclear receptors that respond to cholesterol status. Post-translationally, LCAT requires activation by apolipoproteins, primarily apoA-I, which binds to the enzyme and promotes interfacial activation. ApoE isoforms also activate LCAT, with apoE2, E3, and E4 showing different efficiencies. Additionally, LCAT activity can be modulated by the lipid composition of HDL particles, including the ratio of phosphatidylcholine to sphingomyelin, and by the presence of inhibitors such as apoA-II. Hormonal and metabolic factors, including thyroid hormone and insulin, can influence LCAT expression and activity.
phosphatidylcholine-sterol O-acyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LCAT | Familial LCAT deficiency; corneal opacities, anemia, renal failure | LCAT knockout mouse; patient-derived iPSCs with LCAT mutations |
| LCAT | Atherosclerosis; impaired reverse cholesterol transport | ApoE-/- or LDLR-/- mice with LCAT overexpression or knockout |
| APOA1 | HDL deficiency; cardiovascular risk | APOA1 knockout and transgenic mice |
| APOE | Alzheimer's disease; lipid metabolism; atherosclerosis | APOE isoform-specific knock-in mice |
| CETP | Dyslipidemia; cardiovascular disease | CETP transgenic mice; human CETP expression models |
Familial LCAT deficiency
Mutations in the LCAT gene that abolish or severely reduce phosphatidylcholine-sterol O-acyltransferase activity cause familial LCAT deficiency, an autosomal recessive disorder characterized by corneal opacities, normochromic anemia, proteinuria, and progressive renal failure. The absence of cholesterol esterification leads to very low HDL cholesterol and accumulation of free cholesterol in tissues. Diagnosis is based on clinical features, lipid profile, and genetic testing.
Atherosclerosis and cardiovascular disease
LCAT activity influences atherosclerosis through its role in reverse cholesterol transport. In animal models, LCAT overexpression can be protective or detrimental depending on the context, while LCAT deficiency generally impairs reverse cholesterol transport. Epidemiological studies have linked low LCAT activity to increased cardiovascular risk, but the relationship is complex. Therapeutic strategies aiming to enhance LCAT activity are under investigation for atherosclerosis.
Therapeutic targeting of LCAT
Recombinant LCAT and small-molecule activators have been developed as potential therapies for LCAT deficiency and cardiovascular disease. Clinical trials of HDL-targeted therapies, including LCAT-based approaches, have had mixed results, highlighting the need for better understanding of the enzyme's role in different disease contexts. CRISPR-based disease models can help evaluate the efficacy and safety of such therapies.
From phosphatidylcholine-sterol O-acyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of LCAT impair reverse cholesterol transport? | LCAT knockout mouse or CRISPR knockout in HepG2 cells |
| How do point mutations in LCAT affect catalytic activity? | CRISPR point-mutation knock-in of patient variants in cell lines |
| Can a specific LCAT variant restore activity? | Knock-in of wild-type or mutant LCAT in LCAT-/- cells |
| Where is LCAT expressed and secreted? | Tagged knock-in of LCAT with fluorescent or epitope tag |
| Does LCAT overexpression protect against atherosclerosis? | Transgenic or AAV-mediated LCAT overexpression in mouse models |
| What genes interact with LCAT in HDL remodeling? | CRISPR library screening in lipid-loaded macrophages |
How to Study the phosphatidylcholine-sterol O-acyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LCAT activity assay (radiolabeled) | Rate of cholesteryl ester formation | Diagnosis of LCAT deficiency; enzyme kinetics |
| Fluorogenic LCAT assay | Continuous monitoring of enzyme activity | High-throughput screening for activators/inhibitors |
| Lipidomics (LC-MS/MS) | Cholesteryl ester and phospholipid species | Quantifying LCAT products in cells and plasma |
| Western blot | LCAT protein levels | Assessing expression in cell models |
| qPCR | LCAT mRNA levels | Transcriptional regulation studies |
| CRISPR knockout | Gene function loss | Testing causality of LCAT in lipid metabolism |
| CRISPR knock-in | Specific mutations or tags | Modeling patient variants; tracking protein localization |
| CRISPR library screen | Genome-wide regulators | Identifying modifiers of LCAT activity |
Enzymatic activity assays
LCAT activity is typically measured using exogenous or endogenous substrates. Common methods include the use of radiolabeled cholesterol or phosphatidylcholine and thin-layer chromatography to separate products, or fluorogenic substrates that allow continuous monitoring. These assays can be performed with recombinant LCAT or plasma samples and are used to diagnose LCAT deficiency.
Lipidomics and mass spectrometry
Mass spectrometry-based lipidomics enables comprehensive profiling of cholesteryl esters, phosphatidylcholine species, and lysophosphatidylcholine in cells and plasma. This approach can quantify the products of LCAT activity and reveal changes in lipid metabolism upon genetic manipulation.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that regulate LCAT activity or cholesterol esterification. For example, a screen for regulators of cholesterol efflux or HDL function may uncover modifiers of LCAT pathway. These screens are typically performed in macrophage or hepatocyte cell lines with readouts such as lipid staining or fluorescent cholesterol analogs.
Animal models and in vivo studies
Mouse models with LCAT knockout, overexpression, or human LCAT transgenes are used to study the role of LCAT in atherosclerosis, renal disease, and lipoprotein metabolism. These models can be combined with bone marrow transplantation or AAV-mediated gene delivery to dissect tissue-specific contributions.
How CRISPR Can Be Used to Study GO:0004607 phosphatidylcholine-sterol O-acyltransferase activity
Knockout
CRISPR knockout of LCAT in cell lines such as HepG2 or Huh7 abolishes phosphatidylcholine-sterol O-acyltransferase activity, leading to accumulation of free cholesterol and reduced cholesteryl esters. These models are used to confirm the role of LCAT in cholesterol esterification and to study compensatory pathways. Knockout mice are also available and display similar lipid abnormalities.
Point Mutation
CRISPR point mutation can introduce specific patient-derived missense mutations into the endogenous LCAT locus, allowing study of how these variants affect enzyme activity, stability, and secretion. For example, mutations identified in familial LCAT deficiency can be modeled to understand genotype-phenotype correlations. This approach is more physiologically relevant than overexpression of mutant cDNA.
Knock-in
Knock-in of a fluorescent or epitope tag into the LCAT gene enables tracking of the endogenous protein in cells and tissues. Alternatively, knock-in of human LCAT into mouse models can create humanized models for drug testing. CRISPR-mediated knock-in of disease-associated variants can also be used to test therapeutic strategies.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can increase LCAT levels to study the effects of enhanced activity on HDL maturation and reverse cholesterol transport. Overexpression models are useful for testing whether increasing LCAT activity is protective in atherosclerosis. However, supraphysiological expression may have artifacts, so knock-in of a strong promoter may be preferable.
How EDITGENE Supports phosphatidylcholine-sterol O-acyltransferase activity Research
Researchers studying phosphatidylcholine-sterol O-acyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in lipid metabolism, HDL function, or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to create precisely engineered cell and animal models, enabling rigorous functional studies of LCAT and its regulators.
Contact EDITGENE today to design your custom CRISPR model for phosphatidylcholine-sterol O-acyltransferase activity research.
Frequently Asked Questions About phosphatidylcholine-sterol O-acyltransferase activity
What is phosphatidylcholine-sterol O-acyltransferase activity?
It is an enzymatic activity (GO:0004607) that transfers a fatty acid from phosphatidylcholine to a sterol, producing a sterol ester and lysophosphatidylcholine. In humans, LCAT is the main enzyme with this activity.
What genes are involved in phosphatidylcholine-sterol O-acyltransferase activity?
The primary gene is LCAT, which encodes lecithin-cholesterol acyltransferase. Other genes such as APOA1, APOE, and CETP modulate its activity and pathway.
What is the role of LCAT in cholesterol metabolism?
LCAT esterifies free cholesterol on HDL, driving HDL maturation and reverse cholesterol transport, which moves cholesterol from tissues to the liver.
What diseases are associated with LCAT deficiency?
Familial LCAT deficiency causes corneal opacities, anemia, and renal failure. Low LCAT activity is also linked to atherosclerosis and cardiovascular risk.
How is LCAT activity regulated?
LCAT is activated by apolipoproteins like apoA-I and apoE, and its expression is regulated by nuclear receptors such as LXRs. Lipid composition of HDL also affects activity.
What are the symptoms of familial LCAT deficiency?
Symptoms include corneal clouding, normocytic anemia, proteinuria, and progressive kidney disease. Diagnosis is by genetic testing and lipid analysis.
Can LCAT be targeted for therapy?
Yes, recombinant LCAT and small-molecule activators are being developed for LCAT deficiency and atherosclerosis, though clinical trials have shown mixed results.
What model systems are used to study LCAT?
Common models include LCAT knockout mice, transgenic overexpression mice, and CRISPR-engineered cell lines such as HepG2 and macrophages.
How is LCAT activity measured in the lab?
Activity is measured using radiolabeled or fluorogenic substrates, often with thin-layer chromatography or mass spectrometry to quantify products.
What is the difference between LCAT and ACAT?
LCAT (GO:0004607) esterifies cholesterol on lipoproteins using phosphatidylcholine as acyl donor, while ACAT (SOAT) esterifies cholesterol inside cells using acyl-CoA. They are distinct enzymes.
Conclusion
Phosphatidylcholine-sterol O-acyltransferase activity (GO:0004607) is a fundamental enzymatic function in cholesterol metabolism, primarily executed by LCAT in humans. It is essential for HDL maturation, reverse cholesterol transport, and overall lipid homeostasis, and its dysfunction leads to familial LCAT deficiency and contributes to atherosclerosis. Understanding its mechanism, regulation, and genetic determinants is crucial for developing therapies for cardiovascular and renal diseases. CRISPR-based models offer powerful tools to dissect these pathways with unprecedented precision.
References
- 1. Jonas A. 2000. Lecithin cholesterol acyltransferase.. Biochim Biophys Acta 1529(1-3):245-56 PMID: 11111093
- 2. Ossoli A et al.. 2016. Role of LCAT in Atherosclerosis.. J Atheroscler Thromb 23(2):119-27 PMID: 26607351
- 3. Steinmetz A et al.. 1985. Activation of phosphatidylcholine-sterol acyltransferase by human apolipoprotein E isoforms.. Eur J Biochem 152(3):747-51 PMID: 4054131
- 4. Jonas A. 1998. Regulation of lecithin cholesterol acyltransferase activity.. Prog Lipid Res 37(4):209-34 PMID: 10193526
- 5. Yang K et al.. 2022. LCAT- targeted therapies: Progress, failures and future.. Biomed Pharmacother 147:112677 PMID: 35121343
- 6. Kingwell BA et al.. 2014. HDL-targeted therapies: progress, failures and future.. Nat Rev Drug Discov 13(6):445-64 PMID: 24854407
- 7. Kinoshita M. 1994. [Familial LCAT deficiency].. Nihon Rinsho 52(12):3210-5 PMID: 7853712
- 8. Freeman LA et al.. 2020. Novel lecithin: cholesterol acyltransferase-based therapeutic approaches.. Curr Opin Lipidol 31(2):71-79 PMID: 32073411
